vs
Side-by-side financial comparison of AlTi Global, Inc. (ALTI) and RHYTHM PHARMACEUTICALS, INC. (RYTM). Click either name above to swap in a different company.
AlTi Global, Inc. is the larger business by last-quarter revenue ($86.6M vs $57.3M, roughly 1.5× RHYTHM PHARMACEUTICALS, INC.). AlTi Global, Inc. runs the higher net margin — -15.1% vs -83.0%, a 67.8% gap on every dollar of revenue. On growth, AlTi Global, Inc. posted the faster year-over-year revenue change (87.0% vs 36.9%). Over the past eight quarters, RHYTHM PHARMACEUTICALS, INC.'s revenue compounded faster (48.5% CAGR vs 30.6%).
Cristal Global is the world's second-largest producer of titanium dioxide and a leading producer of titanium chemicals. It was formed when The National Titanium Dioxide Company Ltd. combined with Millennium Chemicals. The headquarters are in Jeddah, Saudi Arabia. It is a significant shareholder in Bemax, the world’s 5th largest TiO2 feedstock producer.
Rhythm Pharmaceuticals is a biopharmaceutical firm focused on developing and commercializing targeted therapies for rare genetic disorders causing severe unmanageable obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome. It serves patients in North America and Europe who lack effective standard treatments for their chronic life-altering conditions.
ALTI vs RYTM — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $86.6M | $57.3M |
| Net Profit | $-13.1M | $-47.5M |
| Gross Margin | — | 91.6% |
| Operating Margin | -2.1% | -82.2% |
| Net Margin | -15.1% | -83.0% |
| Revenue YoY | 87.0% | 36.9% |
| Net Profit YoY | 75.6% | -9.6% |
| EPS (diluted) | — | $-0.73 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $86.6M | $57.3M | ||
| Q3 25 | $57.2M | $51.3M | ||
| Q2 25 | $53.1M | $48.5M | ||
| Q1 25 | $58.0M | $32.7M | ||
| Q4 24 | $46.3M | $41.8M | ||
| Q3 24 | $51.8M | $33.3M | ||
| Q2 24 | $49.5M | $29.1M | ||
| Q1 24 | $50.8M | $26.0M |
| Q4 25 | $-13.1M | $-47.5M | ||
| Q3 25 | $-84.1M | $-52.9M | ||
| Q2 25 | $-24.4M | $-46.6M | ||
| Q1 25 | $1.9M | $-49.5M | ||
| Q4 24 | $-53.8M | $-43.3M | ||
| Q3 24 | $-72.5M | $-43.6M | ||
| Q2 24 | $-6.4M | $-32.3M | ||
| Q1 24 | $29.7M | $-141.4M |
| Q4 25 | — | 91.6% | ||
| Q3 25 | — | 89.3% | ||
| Q2 25 | — | 88.6% | ||
| Q1 25 | — | 88.8% | ||
| Q4 24 | — | 90.9% | ||
| Q3 24 | — | 88.5% | ||
| Q2 24 | — | 89.9% | ||
| Q1 24 | — | 89.2% |
| Q4 25 | -2.1% | -82.2% | ||
| Q3 25 | -49.8% | -102.6% | ||
| Q2 25 | -56.7% | -93.4% | ||
| Q1 25 | -23.3% | -143.7% | ||
| Q4 24 | -42.7% | -98.6% | ||
| Q3 24 | -18.4% | -132.0% | ||
| Q2 24 | -30.2% | -139.2% | ||
| Q1 24 | -28.9% | -538.7% |
| Q4 25 | -15.1% | -83.0% | ||
| Q3 25 | -147.0% | -103.1% | ||
| Q2 25 | -45.9% | -96.1% | ||
| Q1 25 | 3.3% | -151.4% | ||
| Q4 24 | -116.1% | -103.6% | ||
| Q3 24 | -140.0% | -131.2% | ||
| Q2 24 | -12.9% | -110.9% | ||
| Q1 24 | 58.4% | -544.4% |
| Q4 25 | — | $-0.73 | ||
| Q3 25 | — | $-0.82 | ||
| Q2 25 | $-0.33 | $-0.75 | ||
| Q1 25 | $-0.04 | $-0.81 | ||
| Q4 24 | $-0.71 | $-0.71 | ||
| Q3 24 | $-0.88 | $-0.73 | ||
| Q2 24 | $-0.18 | $-0.55 | ||
| Q1 24 | $0.18 | $-2.35 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $41.2M | $388.9M |
| Total DebtLower is stronger | $883.0K | — |
| Stockholders' EquityBook value | $600.1M | $139.1M |
| Total Assets | $1.2B | $480.2M |
| Debt / EquityLower = less leverage | 0.00× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $41.2M | $388.9M | ||
| Q3 25 | $35.8M | $416.1M | ||
| Q2 25 | $42.4M | $291.0M | ||
| Q1 25 | $52.8M | $314.5M | ||
| Q4 24 | $64.4M | $320.6M | ||
| Q3 24 | $220.6M | $298.4M | ||
| Q2 24 | $60.0M | $319.1M | ||
| Q1 24 | $134.2M | $201.2M |
| Q4 25 | $883.0K | — | ||
| Q3 25 | $586.0K | — | ||
| Q2 25 | $673.0K | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $0 | — | ||
| Q3 24 | $128.4M | — | ||
| Q2 24 | $164.0M | — | ||
| Q1 24 | $183.7M | — |
| Q4 25 | $600.1M | $139.1M | ||
| Q3 25 | $607.2M | $148.8M | ||
| Q2 25 | $685.4M | $-11.9M | ||
| Q1 25 | $665.2M | $18.9M | ||
| Q4 24 | $658.4M | $21.7M | ||
| Q3 24 | $707.0M | $11.2M | ||
| Q2 24 | $540.2M | $39.3M | ||
| Q1 24 | $510.9M | $61.6M |
| Q4 25 | $1.2B | $480.2M | ||
| Q3 25 | $1.2B | $506.9M | ||
| Q2 25 | $1.2B | $372.7M | ||
| Q1 25 | $1.2B | $386.7M | ||
| Q4 24 | $1.3B | $392.3M | ||
| Q3 24 | $1.4B | $363.6M | ||
| Q2 24 | $1.3B | $381.8M | ||
| Q1 24 | $1.3B | $258.7M |
| Q4 25 | 0.00× | — | ||
| Q3 25 | 0.00× | — | ||
| Q2 25 | 0.00× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.00× | — | ||
| Q3 24 | 0.18× | — | ||
| Q2 24 | 0.30× | — | ||
| Q1 24 | 0.36× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-51.4M | $-25.4M |
| Free Cash FlowOCF − Capex | $-52.2M | — |
| FCF MarginFCF / Revenue | -60.3% | — |
| Capex IntensityCapex / Revenue | 0.9% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-51.4M | $-25.4M | ||
| Q3 25 | $-53.5M | $-26.6M | ||
| Q2 25 | $-19.9M | $-23.3M | ||
| Q1 25 | $-30.2M | $-40.4M | ||
| Q4 24 | $-50.7M | $-18.8M | ||
| Q3 24 | $-4.9M | $-25.2M | ||
| Q2 24 | $-30.2M | $-29.1M | ||
| Q1 24 | $-15.5M | $-40.7M |
| Q4 25 | $-52.2M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $-20.0M | — | ||
| Q1 25 | $-31.0M | — | ||
| Q4 24 | $-58.2M | — | ||
| Q3 24 | $-9.4M | — | ||
| Q2 24 | $-31.2M | — | ||
| Q1 24 | $-15.7M | — |
| Q4 25 | -60.3% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -37.6% | — | ||
| Q1 25 | -53.4% | — | ||
| Q4 24 | -125.7% | — | ||
| Q3 24 | -18.2% | — | ||
| Q2 24 | -63.2% | — | ||
| Q1 24 | -30.9% | — |
| Q4 25 | 0.9% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 1.3% | — | ||
| Q4 24 | 16.3% | — | ||
| Q3 24 | 8.7% | — | ||
| Q2 24 | 2.2% | — | ||
| Q1 24 | 0.4% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -15.80× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -0.52× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ALTI
| Management Advisory Fees | $51.1M | 59% |
| Other | $32.7M | 38% |
| Distributions From Investments | $2.9M | 3% |
RYTM
Segment breakdown not available.
